ArticleTargeted oncology2026

Real-World Outcomes of Adjuvant Pembrolizumab for Renal Cell Carcinoma: The Potential Role of PD-L1 as a Prognostic Biomarker.

Hiroki Ishihara et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.